ExpreS2ion to present in upcoming investor and scientific events
Hørsholm, Denmark, 31 October2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor and scientific events, including BIO-Europe, the Protein & Antibody Engineering Summit Europe, a 2024 Third Quarter Results Webinar, and the LSX Investival Showcase.
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website and via the links below.
4-6 November 2024 | BIO-Europe 2024
Stockholm, Sweden
CEO Bent Frandsen will represent ExpreS2ion at BIO-Europe in Stockholm, 4 – 6 November. To pre-arrange a meeting, please contact us via email on info@expreS2ionbio.com. More information is available on BIO-Europe’s website.
5-7 November 2024 | Protein & Antibody Summit Europe
Barcelona, Spain
PEGS Europe is the largest protein & antibody engineering event in Europe, and in 2024 includes an entire stream devoted to Oncology. ExpreS2ion's SVP of R&D and Technology, Max Soegaard, will represent the company. For more information, please visit the event website.
14 November 2024 | Presentation of 2024 Third Quarter Results
11:00 – 11:30 | Virtual
ExpreS2ion CEO Bent Frandsen and CFO Keith Alexander will present 2024 third quarter interim results and take questions from investors. Please register via the ExpreS2ion landing page on the Inderes website in the weeks leading up to the webcast.
18 November 2024 | LSX Investival Showcase
London, UK
The Investival Showcase is a Biotech, Healthtech and Medtech networking event for startup, growth stage and publicly listed companies. CFO Keith Alexander will participate. To schedule a meeting, please contact us via investor@expres2ionbio.com. More information is available on the LSX website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.